[Click eStock] "Eutilex, a Cancer Drug Company Completely Changing This Year"

[Asia Economy Reporter Jang Hyowon] Hanyang Securities forecasted on the 12th that Utilex possesses technology recognized by everyone and is expected to produce results this year.

Analyst Oh Byung-yong of Hanyang Securities stated in a report on the same day, “Utilex is a new drug development company that is developing the representative cancer immunotherapy drug ‘AppB&T’ using autologous T cells and the antibody cancer drug ‘EU101’ targeting ‘4-1BB’,” adding, “The founder, Dr. Kwon Byung-se, was the first in the world to discover the T cell activation factor ‘4-1BB’ in 1989 and is regarded as a world-renowned immunology scholar.”

Researcher Oh said, “This year, the company’s research team will finally begin clinical trials of new drug candidates utilizing ‘4-1BB,’ which they have studied for decades, and we will be able to see the results,” analyzing, “It will be a year when a full reevaluation of the pipeline’s value is expected.”

The T cell therapy drug ‘AppB&T’ is currently recruiting its first patient for phase 2 clinical trials. It is explained that excellent efficacy is expected from the very first patient. He emphasized the need to pay attention to the T cell therapy drug ‘AppB&T,’ which is currently in the patient recruitment stage of phase 2 clinical trials.

He explained, “The results of phase 1 clinical trials conducted on terminal blood cancer patients in the past were very excellent,” and “Since both of the two NK/T lymphoma patients who participated in phase 1 achieved complete remission, there is considerable expectation from the very first patient in phase 2.”

He added, “One of the reasons why the stock price of Boxel Bio recently rose sharply is that complete remission began to appear from the very first patient in phase 2 clinical trials,” and “Utilex will also disclose the results from its first patient. The data release is scheduled for the third quarter of this year, and a complete remission story similar to Boxel Bio’s can be expected.”

Furthermore, he analyzed, “The company’s initial public offering price was 50,000 KRW, and the current stock price is still only 55,600 KRW, which is close to the IPO price,” adding, “Considering that the bio industry stock prices are at historic highs and that the stock prices of competing cell therapy companies such as Boxel Bio, Green Cross LabCell, and SCM Lifescience have risen sharply, the current stock price appears to be at a reasonable level.”